Mike

When nothing goes right, go left.

[JP @jamvest20]

$PRTG
SITC (Nov 23) data being presented on their lead two drugs -both solely owned
Funding cleared up , data coming , clear upward trajectory on stock trading well below NAP

[SEED Innovations Limited @SEEDInnov]

🔍 With £7.1 million in cash and receivables, SEED is well-positioned to capitalise on future investment opportunities in the health, wellness, and biotech sectors.  https://t.co/kEuG8hts17
#InvestmentOpportunities #SEED

[Ed McDermott @edmcdermott12]

£7.1m of cash and receivables represent circa 3.3p which includes zero value for the investee companies. To name a few of our investments and the current holding values:
Juv - £2.56m
Avextra - £1.9m
Clean Food Group - £965k
#SEEDinnov #Seed

[David Burton ⭐️⭐️ @DavidBurton1971]

Check the BID out on #SEED

DYOR. Cash cow galore this. Share buy-back flagged PLUS you know no dirty placing round the corner!!

Stick my neck out with a 9p p/t working all the numbers/cash/assets out.

#WhatsNotToLike

[Andrew Neal @Andrew_Neal123]

#SEED sat way below cash/assets

£10m NAV with plenty of news ahead

Talk of possible share buy back scheme as per AGM

+10% on small volume

[GMF78 @GMF782]

$PRTG collaboration with #merck announced on PORT6 and PORT7 with #keytruda

https://t.co/G7TYCjLOxI

[JP @jamvest20]

$PRTG
strong news from my biggest LTH.
2nd collab with Merck in 16 months
Trading below NAV and huge upside potential.
Solid results seen following asco , CR in a number of patients.
One stock to keep dialed into.
Next horizon/biohaven in the making

[Share_Talk ™ @Share_Talk]

Shares of #SEED have finally started to turn around in recent weeks, finding good support above 2p, and chart-wise looking to head to 3p over the coming weeks. The arrival of Mr Pascual, apparently something of a high flyer (Level III, CFA), could help this recovery along. @ZaksTradersCafe

[Mike @dj_papz]

$PRTG Portage Biotech announce dosing of the 1st patient in a Phase 1a trial, evaluating their adenosine 2A receptor inhibitor in select solid tumors. #adenosine 🎯

[Portage Biotech @PortageBiotech]

We’re excited to announce that we have dosed the first patient in our Phase 1a trial evaluating our adenosine 2A receptor inhibitor in select solid tumors. We look forward to exploring our next-gen approach to target the #adenosine pathway. Learn more: https://t.co/BmxmMikA9z

[Mike @dj_papz]

$PRTG Portage Biotech #iNKT 🎯

[Portage Biotech @PortageBiotech]

While at #ASCO23, our CEO Dr. Ian Walters spoke with @OncologyTube about Portage’s updated data on its #iNKT engager for the treatment of #melanoma and #NSCLC. Learn more about the #clinicaltrial results here: https://t.co/HgajVWbjsB

[Ed McDermott @edmcdermott12]

#SEEDinnov is trading at circa £3.85m mkt cap (1.8p) with cash at hand of £2.5m plus receivables of £2.5m in April 2024. Our last recorded NAV at September 2022 recorded a 7.84p or £16.689m valuation.

[Just Us @Nightroads]

$PRTG @PortageBiotech some very good news coming out today at #ASCO2023. #iNkt “Several target lesions were substantially reduced in size or completely resolved, and a majority of target lesions being clinically stable after twelve weeks,” said Dr. Ian Walters.

[JP @jamvest20]

$PRTG huge PR coming in the next week or so on early efficacy seen in their lead #inkt asset imm60.
NSCLC
100% patients prior pd-1
No grade 3-5
19 lesions (2CR /10 SD /1 MR /6 PR
All at low/ mid dose range
Results be it early are up there with KEYTRUDA! $21bn pa drug!
#ASCO23

[Just Us @Nightroads]

$PRTG. It’s a big deal!!

[Just Us @Nightroads]

$PRTG. We’ve waited a few years for confirmation. I like what I am reading.

[GMF78 @GMF782]

$PRTG “well tolerated” “no MTD was determined” “2 lesions completely resolved” we can’t forget these patients have sadly been through several other treatments that failed. Well done @PortageBiotech you seem to be improving outcomes with PORT2 🙏 #ASCO23 #CancerResearch

[JP @jamvest20]

$prtg CR in target lesions without establishing MTD.

Patients have failed all other treatments so quite incredible early results seen

#ASCO23